By Benff - Own work, CC BY-SA 4.0, https://commons.wikimedia.org/w/index.php?curid=128081038In both, liver fibrosis and resolution of MASH, Novo Nordisk’s GLP1 modulator semaglutide has shown convincing results in the Phase III ESSENCE study suggesting a label extension of the obesity blockbuster.
Tag Archive for: semaglutide
Novo Nordisk A/S invests €726m to expand facilities and to produce APIs to supply the company’s global clinical trials.